HAIFA, Israel, June 16, 2014
HAIFA, Israel, June 16, 2014 /PRNewswire/ --
OHK Medical Devices the leading manufacturer of the HemaClear® tourniquet announces the Journal of Surgery Research and Practice publication of Templeton-Ward et al study titled "The Use of the S-Mart Tourniquet in Hand Surgery: a Safe and Effective Way to Provide a Bloodless Field" (http://dx.doi.org/10.1155/2014/402184).
The study details the safety and effectiveness of exsanguination and bleeding control when the HemaClear is used in hand surgery in the UK.
The authors stressed the following advantages:
?Reduced Tourniquet Times ?Less Interference with the Operative Field ?Outstanding field dryness "In our experience, the use of the S-MART exsanguination tourniquet is an effective and safe way to provide a bloodless field in hand and wrist surgery" (Templeton-Ward et al, 2014).
The study was promoted by a derogative comment in Noordin et al (http://jbjs.org/content/91/12/2958) about the potential risks of the ultra-narrow HemaClear (S-MART). The study authors clearly state "We experienced very few complications as a result of its use as suggested in Noordin's article, and we feel that its benefits certainly outweigh any risks in its use."
About OHK
OHK Medical Devices, a privately held company headquartered in Haifa, Israel is the world leader in sterile tourniquet solutions. The HemaClear sterile tourniquet product is the first significant advancement in tourniquet solutions in over 10 years and the world's leading solution for bloodless orthopedic surgery. An innovative and groundbreaking technology has taken the orthopedic operating room to a new level. Since penetrating the market in 2008 HemaClear has been successfully used in over 600,000 procedures in over 2,000 operating rooms across 30 countries. For more information about OHK's HemaClear, visit http://www.hemaclear.com or contact Hallie Keren at Hallie@hemaclear.com or +972-54-782-7865
SOURCE OHK Medical Devices
Help employers find you! Check out all the jobs and post your resume.
